Agilent Technologies FY2024 Revenue Decreased 4.8%

Executive Summary

In FY2024, Agilent Technologies reported a total revenue of $6.51 billion, representing a 4.8% decline compared to the previous fiscal year’s $6.83 billion. Despite the revenue decrease, net income increased slightly by 4.0% to $1.29 billion from $1.24 billion. The company maintained a strong cash flow from operations at $1.75 billion, supporting ongoing investments and shareholder returns. The balance sheet shows a solid liquidity position with cash and cash equivalents totaling $1.33 billion and total assets of $11.85 billion. Leverage remains manageable with long-term debt at $3.33 billion, and stockholders’ equity stands at $5.89 billion, reflecting stable capital structure. The company’s strategic acquisitions and divestitures, including the recent BIOVECTRA acquisition, are expected to enhance long-term growth prospects. Overall, despite top-line pressure, Agilent’s profitability and cash generation demonstrate resilience in a competitive market environment.

Key Metrics

Management Discussion and Analysis

Despite a challenging macroeconomic environment, Agilent Technologies demonstrated robust financial management in FY2024. The revenue decline was primarily driven by softness in certain end markets, including chemicals and advanced materials, which saw a 3.0% decrease. The company’s focus on high-margin segments such as diagnostics and genomics helped sustain profitability, with net income rising 4.0% year-over-year. Strategic acquisitions, notably BIOVECTRA, contributed to asset growth and expanded capabilities in contract development and manufacturing. The company’s disciplined cost control measures, including restructuring initiatives and facility consolidations, mitigated margin compression. Cash flow from operations remained strong, supporting ongoing R&D investments and shareholder returns through dividends and share repurchases. The balance sheet remains healthy, with a solid liquidity position and manageable leverage. Looking ahead, Agilent aims to leverage its diversified portfolio and strategic acquisitions to drive long-term growth, while navigating supply chain and market uncertainties.

Income Statement Analysis

Revenue for FY2024 was $6.51 billion, down 4.8% from $6.83 billion in FY2023. Gross profit margin improved slightly to 54.0% from 50.4%, reflecting better product mix and cost management. Operating income increased by 10.1% to $1.49 billion, driven by lower operating expenses and restructuring benefits. Net income rose 4.0% to $1.29 billion, with earnings per share (diluted) at $4.43, up from $4.19. The company’s focus on high-margin diagnostics and genomics segments helped offset revenue pressures. The net margin remained stable at approximately 19.8%, indicating efficient cost control amidst revenue decline. The YoY and QoQ trends suggest resilience in profitability despite top-line softness, supported by strategic cost initiatives and product mix improvements.

Balance Sheet Analysis

As of October 31, 2024, total assets increased by 10.2% to $11.85 billion from $10.76 billion. Cash and cash equivalents stood at $1.33 billion, providing liquidity for acquisitions and share repurchases. Accounts receivable increased marginally to $1.32 billion, while inventory decreased slightly to $972 million, reflecting inventory management efforts. Property, plant, and equipment rose to $1.78 billion, mainly due to recent acquisitions and expansion activities. Total liabilities increased to $5.95 billion, with long-term debt at $3.33 billion, up 21.9% YoY, primarily due to new debt issuance for acquisitions. Stockholders’ equity grew modestly to $5.89 billion, supported by retained earnings and share repurchases. The balance sheet demonstrates a strong liquidity position and manageable leverage, positioning the company well for future strategic initiatives.

Cash Flow Analysis

Cash flows from operating activities were $1.75 billion, slightly lower than $1.77 billion in FY2023, reflecting the revenue decline but stable cash generation. Capital expenditures increased to $378 million from $310 million, mainly due to investments in manufacturing capacity and technology infrastructure. Free cash flow remains healthy, enabling continued share repurchases and dividend payments. During FY2024, the company repurchased approximately 8.4 million shares for $1.15 billion and paid dividends totaling $274 million. Financing activities included debt issuance of $1.2 billion and repayment of $600 million, maintaining a balanced capital structure. The company’s cash flow profile underscores its ability to fund growth initiatives and return value to shareholders while maintaining financial flexibility.

Ratios & DuPont Analysis

Net profit margin stood at 19.8%, indicating efficient cost management. Return on assets (ROA) was approximately 10.9%, driven by net income and total assets. Return on equity (ROE) was about 21.9%, reflecting effective use of shareholders’ capital. Asset turnover ratio was 0.55, showing moderate utilization of assets to generate revenue. The equity multiplier was 2.01, indicating a balanced leverage position. The DuPont analysis confirms that profitability is primarily driven by net margin and asset efficiency, with leverage playing a supporting role. The company’s financial ratios suggest stable profitability and prudent capital management, supporting long-term shareholder value creation.

Risk Factors

Key risks include market competition from emerging technologies, supply chain disruptions, geopolitical uncertainties affecting global operations, regulatory changes in key markets, and macroeconomic volatility impacting customer demand. Additionally, the company faces risks related to integration of acquisitions, intellectual property protection, and currency fluctuations. Macro risks such as inflation and interest rate changes could affect borrowing costs and profitability. The company actively manages these risks through diversified product portfolios, strategic sourcing, and hedging strategies, but uncertainties remain that could impact future performance.

Notes & Additional Commentary

FY2024 included a $6 million impairment of in-process R&D, primarily related to a project in the life sciences segment. The divestiture of Resolution Bioscience in FY2023 resulted in a $43 million gain and a $13 million goodwill adjustment. Unusual items such as asset impairments and restructuring costs totaled $76 million, reflecting ongoing efficiency initiatives. The company’s acquisition of BIOVECTRA for $915 million expanded its contract manufacturing capabilities, with expected synergies. Foreign currency translation impacts and tax benefits from Singapore’s tax holiday contributed to stable net income and cash flow. The company’s strategic focus remains on high-margin segments and disciplined capital allocation to sustain growth amid market challenges.

Investment Implications

In the short term, investors should monitor revenue trends and margin stability, especially in cyclical end markets. The company’s strong cash flow and manageable leverage support ongoing buybacks and dividend payments, providing shareholder value. Long-term, Agilent’s diversified portfolio, strategic acquisitions, and focus on high-growth segments position it well for sustained growth. Risks include market competition, geopolitical factors, and integration challenges. A balanced outlook suggests cautious optimism, with opportunities for growth driven by innovation and market expansion, balanced against macroeconomic uncertainties.